Subscribe to thousands of academic journals for just $40/month
Read and share the articles you need for your research, all in one place.

OROS Methylphenidate-Induced Skin Eruptions


Mary Ann Liebert, Inc.
Copyright 2009, Mary Ann Liebert, Inc.
Letters to the Editor
Publisher site
See Article on Publisher Site

Preview Only

Expand Tray Hide Tray

OROS Methylphenidate-Induced Skin Eruptions


Letter to the Editor OROS Methylphenidate-Induced Skin Eruptions Murat Coskun, M.D., Mustafa Deniz Tutkunkardas, M.D., and Salih Zoroglu, M.D. ethylphenidate (MPH) has rarely been reported to cause skin eruptions (SE) in subjects with attentiondeficit=hyperactivity disorder (ADHD) (Cohen et al. 1992; Confino and Goldberg 2005). Here we report the case of an 8-year-old boy with ADHD who developed maculopapular pruritic SE with OROS MPH (Concerta) but not with immediate release (IR) MPH (Ritalin) treatment. Case Report The subject is an 8-year-old boy who presented with his mother due to typical symptoms of ADHD. He was given a diagnosis of ADHD combined type with normal intellectual capacity. His prenatal, postnatal, and early developmental history was unremarkable. He had a generalized tonic–clonic seizure at 3 years of age, but has been seizure free since then. He had been on valproate 150– 250 mg=day treatment between 3 and 4 years of age. However because his control electroencephalogram (EEG) revealed abnormality, he was restarted with valproate 400 mg=day for the last 3 months. He has no known drug or food allergies so far. He has never been treated with any psychopharmacological agent except for the previous and current antiepileptic treatments. No dermatologic reactions
Loading next page...

Preview Only. This article cannot be rented because we do not currently have permission from the publisher.